NovoCureNVCR
NVCR
About: NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Employees: 1,453
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
289% more call options, than puts
Call options by funds: $68.8M | Put options by funds: $17.7M
150% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 5 (+3) [Q4]
87% more capital invested
Capital invested by funds: $1.46B [Q3] → $2.73B (+$1.27B) [Q4]
53% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 34
5% more funds holding
Funds holding: 222 [Q3] → 234 (+12) [Q4]
2.11% less ownership
Funds ownership: 86.7% [Q3] → 84.59% (-2.11%) [Q4]
16% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 77
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
36%
upside
Avg. target
$37
66%
upside
High target
$42
90%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar 22% 1-year accuracy 34 / 154 met price target | 72%upside $38 | Buy Reiterated | 14 Jan 2025 |
Piper Sandler Jason Bednar 45% 1-year accuracy 17 / 38 met price target | 90%upside $42 | Overweight Maintained | 13 Dec 2024 |
Evercore ISI Group Vijay Kumar 53% 1-year accuracy 25 / 47 met price target | 36%upside $30 | Outperform Upgraded | 2 Dec 2024 |
Financial journalist opinion
Negative
Zacks Investment Research
1 day ago
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
Business Wire
1 month ago
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
BAAR, Switzerland--(BUSINESS WIRE)--Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland.
Neutral
Business Wire
1 month ago
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update.
Neutral
Business Wire
1 month ago
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference.
Positive
The Motley Fool
2 months ago
Why NovoCure Stock Was Winning Big This Week
Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum was helped by price target increases from analysts.
Positive
The Motley Fool
2 months ago
Novocure Has Already Doubled in 2024. Can It Soar Higher in 2025?
The life science industry recently gave folks diagnosed with pancreatic cancer the best news this group has received in a very long time. A new treatment option that significantly raises their chances for long-term survival could become widely available next year.
Positive
Seeking Alpha
2 months ago
NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer
NovoCure's TTFields therapy, combined with standard chemotherapy, significantly improves overall survival in advanced pancreatic cancer, showing a 33% improvement in two-year survival rates. Despite past challenges, NVCR's recent positive data, strong commercial numbers, and robust cash position suggest a potential turnaround and long-term growth. Key upcoming catalysts include FDA submission and potential approval for pancreatic cancer, with a strong cash position supporting continued development and commercialization efforts.
Positive
Zacks Investment Research
2 months ago
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
Positive
Seeking Alpha
2 months ago
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Positive results achieved from phase 3 PANOVA-3 study using TTFields + Gemcitabine + Nab-paclitaxel to treat unresectable, locally advanced 1st-line pancreatic cancer patients. Multiple regulatory submissions, of TTFields therapy combination targeting locally advanced 1st-line pancreatic cancer patients, expected throughout 2025. Data from phase 2 PANOVA-4 trial, using TTFields + TECENTRIQ + Gemcitabine + Nab-paclitaxel to treat 1st-line metastatic pancreatic cancer patients, expected in 2026.
Positive
Benzinga
2 months ago
NovoCure's Tumor-Treating Electric Fields Shows Promise In Pancreatic Cancer Patients
On Monday, NovoCure Ltd NVCR and Zai Lab Limited ZLAB revealed topline data from the Phase 3 PANOVA-3 trial of Tumor-Treating Fields (TTFields) therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Charts implemented using Lightweight Charts™